FOLH1 and neuroendocrine neoplasm: The estimation of the absorbed dose in several OAR (Organs At Risk) and identifiable lesions will be performed from SPECT images with the dosimetry workflow that has already been developed and used on previous treatments in our institution (Lutathera for neuroendocrine tumors, 177Lu-PSMA-1 for prostate cancer) [27–29].